• Abbott Laboratories (NYSE:ABT) is pursuing the acquisition of Exact Sciences to expand its presence in cancer diagnostics.
• The move comes alongside a targeted turnaround plan for Abbott's Nutrition segment after a recent revenue shortfall.
• Management is focusing on pricing actions and new product launches in Nutrition, with an internal goal of segment recovery in the second half of 2026.

Abbott Laboratories, trading at $108.77, is shifting focus toward higher value cancer diagnostics while working to address weaker performance in its Nutrition business. The share price has seen a 10.7% decline over the past week and 12.9% over the past month, with a 12.4% decline year to date and a 14.4% decline over the past year. Over a 3 year period, the stock shows a 5.1% return, while the 5 year return stands at a 2.7% decline.

For investors watching NYSE:ABT, the combination of a potential Exact Sciences acquisition and Nutrition turnaround efforts points to a period of active portfolio reshaping. How effectively Abbott integrates cancer diagnostics and stabilizes Nutrition may influence how the market reassesses the current share price and recent performance trends.

Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.

For you as a shareholder, this update reflects Abbott leaning harder into higher margin diagnostics and devices while working to repair a weaker Nutrition arm. The pending Exact Sciences acquisition would deepen its reach in cancer testing, while Q4 results show group sales at US$11.459b and diluted EPS of US$1.01. Execution on cost control, integration, and mix shift will be important as management targets organic growth of 6.5% to 7.5% and adjusted EPS growth of 10% in 2026.

Abbott Laboratories Narrative, Put to the Test

Recent commentary has highlighted Abbott as a diversified healthcare name with a long dividend history, double digit EPS growth in 2025, and growth engines such as FreeStyle Libre, Volt PFA and now cancer diagnostics. This earnings miss in Nutrition and the pivot toward Exact Sciences may push investors to reassess the long term story, weighing consistent dividend increases and medical device momentum against the Nutrition reset and a step up in M&A activity.

Risks and Rewards in Focus

• 🎁 Medical Devices, diabetes care and electrophysiology are cited as key growth drivers, supported by a strong new product pipeline.
• 🎁 Analysts generally maintain positive ratings, and the P/E of 28.6x is below the Medical Equipment industry average of 32x, with some targets indicating upside from current levels.
• ⚠️ Nutrition sales declined 8.9% in Q4, with volume pressure, loss of a major U.S. WIC contract and pricing actions weighing on results.
• ⚠️ The Exact Sciences deal and guidance tied to a Nutrition turnaround by the second half of 2026 introduce integration and execution risk, especially after a quarter that missed revenue expectations.

What To Watch Next

Looking ahead, it is worth tracking how quickly Nutrition volumes respond to new pricing and launches, how cancer diagnostics are integrated, and whether 2026 growth targets hold as more data comes through earnings. If you want to see how other investors are interpreting this shift in Abbott’s story, you can check out community narratives by following this independent analysis link.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.